Breakthrough T1D has shifted the focus of this opportunity from cardiovascular disease trials to translational research on vascularization for islet replacement therapies. Along with this new objective, the maximum funding amount has been reduced to $900,000 over three years. Please update your calendar, as the Letter of Intent deadline is now January 28, 2026, followed by full proposals on March 11, 2026.
Funder: Breakthrough T1D
Due Dates: January 28, 2026 (LOI) | March 11, 2026 (Full Proposal)
Funding Amounts: Up to $900,000 total for up to 3 years; for-profit applicants use the IDDP mechanism (no indirect costs).
Summary: Supports translational research to enhance and monitor vascularization for durable islet replacement therapies in type 1 diabetes.
Key Information: LOI required; for-profit applicants must contact Breakthrough T1D prior to submission.